Eli Lilly, Pfizer End Program for Tanezumab Pain Drug
October 26 2021 - 8:17AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. and Pfizer Inc. have ended development of a
proposed osteoarthritis pain drug following negative feedback from
U.S. and European regulators, Eli Lilly said Tuesday.
The Indianapolis drugmaker said the companies have discontinued
their global clinical development program for tanezumab, an
investigational nerve growth factor inhibitor that they have been
collaborating on since 2013.
Eli Lilly said the companies made the decision after receiving a
complete response letter from the U.S. Food and Drug
Administration, indicating that the agency wouldn't approve their
application for tanezumab in its current form.
An FDA advisory committee in March had voted overwhelmingly that
the risks of the drug outweighed its benefits, even with a
risk-mitigation strategy put forward by the companies.
The European Medicines Agency's Committee for Medicinal Products
for Human Use last month recommended against approval of the drug
in Europe.
New York-based Pfizer and Eli Lilly agreed in 2013 to develop
and commercialize tanezumab, part of an investigational class of
non-opioid pain medications known as nerve growth factor
inhibitors, in a bid to address significant unmet needs in
moderate-to-severe osteoarthritis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 26, 2021 08:02 ET (12:02 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024